GL1X · GenesisL1 explorer

Research workbench

Human RAB8A phosphorylated at SER111 in complex with gppnp

Analyse Human RAB8A phosphorylated at SER111 in complex with gppnp in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
6STG
Type
protein
Length
341 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
RAS-related protein rab-8A
UniProt
P61006
Ligands
GNP, MG
Pockets
2 · best druggability 0.55

Structure

x-ray diffraction · 2 distinct chains · 39% helix, 27% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ARAS-related protein rab-8Aprotein17238% helix, 27% strandP61006
BRAS-related protein rab-8Aprotein16939% helix, 27% strandP61006

Ligands and binding sites

  • GNP · Phosphoaminophosphonic acid-guanylate ester · ligand · 2 copies · chains A, B
  • MG · Magnesium ion · metal · 2 copies · chains A, B
  • TRS · 2-amino-2-hydroxymethyl-propane-1,3-diol · additive · chains B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

2 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
11460.550.8129GNP, MG
21200.460.7828GNP, MG

Interfaces

1 interface between chains.

  • A–B · 1118 Ų buried · 14 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 2 modified (phosphorylation).

Compared structures

  • 6STG · Human Rab8a phosphorylated at Ser111 in complex with GPPNP · the same entry in another collection · chain A against A, TM-score 1.00
  • P61006 · AlphaFold monomer V2.0 prediction for RAS-related protein rab-8A (P61006) · a predicted model of the same protein · chain B against A, TM-score 0.99

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.